<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Denton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Systemic sclerosis (SSc; scleroderma) encompasses a spectrum of related disorders, most of which share a characteristic clinical feature of skin thickening due to an excess of collagen fibers. The simplest division of the scleroderma-related disorders is into localized  (<a class="graphic graphic_table graphicRef60398" href="/z/d/graphic/60398.html" rel="external">table 1</a>) and systemic forms  (<a class="graphic graphic_table graphicRef80559" href="/z/d/graphic/80559.html" rel="external">table 2</a>) (see  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>). Patients with the systemic forms are more likely to have internal organ involvement, which is usually the target of therapy.</p><p>Differentiating between localized and systemic disease and understanding of the SSc subsets, disease staging, and organ involvement are needed to guide effective use of available therapies.</p><p>The etiology and pathogenesis of SSc are poorly understood. As a result, treatment of these conditions is difficult, incomplete, and not curative. (See  <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">"Risk factors for and possible causes of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">"Pathogenesis of systemic sclerosis (scleroderma)"</a>.)</p><p>An overview of the management of adults with SSc will be discussed here. Pretreatment evaluation, systemic immunologic modulation, potentially antifibrotic approaches, and localized scleroderma and SSc in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7544.html" rel="external">"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">"Juvenile localized scleroderma"</a> and  <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">"Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2279365952"><span class="h1">OVERVIEW OF PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Prior to initiating therapy for systemic sclerosis (SSc), it is helpful to know whether the patient has limited or diffuse skin involvement and/or has overlap features.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse skin involvement</strong> – Patients with diffuse skin disease (or diffuse cutaneous SSc [dcSSc] subset) are more likely to also have involvement of internal organs, particularly the lung, heart, and kidneys.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited skin involvement</strong> – Patients with limited skin involvement (or limited cutaneous SSc [lcSSc] subset) generally have prominent vascular manifestations including severe Raynaud phenomenon, cutaneous telangiectasia, and less commonly, pulmonary hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No skin involvement</strong> – Up to 10 percent of patients have internal organ involvement without skin involvement, referred to as SSc sine scleroderma. These patients are generally managed in a way similar to those classified as having the limited cutaneous SSc subset, with a focus on vascular symptoms and internal organ complications. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Systemic sclerosis sine scleroderma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overlap syndromes</strong> – Patients with features of other autoimmune rheumatic diseases (eg, systemic lupus erythematosus, polymyositis) may require a different therapeutic approach which is guided by the predominant features of the overlap syndrome (eg, arthritis, myositis). (See  <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"</a>.)</p><p></p><p>Certain autoantibodies are associated with disease subsets and may help predict the risk of future organ involvement  (<a class="graphic graphic_table graphicRef59732" href="/z/d/graphic/59732.html" rel="external">table 3</a>), including lung fibrosis [<a href="#rid1">1</a>]. Detailed discussions of the classification of disease subsets and clinical manifestations of SSc are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Background'</a>.)</p><p>An organ-based pretreatment evaluation is presented separately (See  <a class="medical medical_review" href="/z/d/html/7544.html" rel="external">"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H9866624"><span class="h1">GENERAL PRINCIPLES OF MANAGEMENT</span><span class="headingEndMark"> — </span>The aim of immunosuppressive therapy is to reduce progression or severity of systemic sclerosis (SSc) complications. Treatment should be started as early as possible in the disease course to slow disease progression before further damage occurs. Our management approach is generally consistent with guidelines developed by professional organizations [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H1346909262"><span class="h2">Organ-based approach to therapy</span><span class="headingEndMark"> — </span>Due to the wide spectrum of disease manifestations and organ involvement, the management of the disease is tailored to the individual patient, taking into account the disease subset and type of internal organ involvement. In general, patients with SSc are treated with therapy to reduce symptoms and to impact organ-based disease. As examples, patients with gastrointestinal reflux are treated with proton-pump inhibitors, patients with Raynaud phenomenon are frequently treated with calcium channel blockers, and patients with hypertensive scleroderma renal crisis are treated with angiotensin-converting enzyme (ACE) inhibitors. Selection of immunosuppression, if indicated, is based on the organ requiring the most aggressive therapy.</p><p class="headingAnchor" id="H2165739819"><span class="h2">Severe or rapidly progressive disease</span><span class="headingEndMark"> — </span>Patients with diffuse skin involvement and/or severe inflammatory organ involvement are usually treated more aggressively with systemic immunosuppressive therapy because of the increased risk of complications and organ failure. This includes patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse skin involvement that is severe or progressive (see <a class="local">'Initial therapy'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial lung disease (see  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Choice of initial agent'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis (see <a class="local">'Myocarditis'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe inflammatory myopathy and/or arthritis (see <a class="local">'Inflammatory myopathy'</a> below and <a class="local">'Joint involvement'</a> below)</p><p></p><p>In particular, patients identified as having severe or rapidly progressive diffuse skin or clinically significant lung disease that is extensive on computed tomography (CT) or clearly progressive on serial assessment should be evaluated and managed in specialized centers with expertise for SSc [<a href="#rid2">2,3</a>]. Intensive immunosuppression and autologous hematopoietic stem cell rescue may benefit some poor-prognosis cases of SSc [<a href="#rid4">4,5</a>]. Other patients may be candidates for investigational therapies, possibly in the context of clinical trials [<a href="#rid6">6</a>]. Various immunosuppressive and antifibrotic drugs, including investigational therapies, for the treatment of SSc are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H3859672386"><span class="h2">Avoidance of glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids have been identified as a risk factor for scleroderma renal crisis. In a study of 110 patients with SSc, scleroderma renal crisis was associated with the use of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> doses of 15 mg daily (or greater) [<a href="#rid7">7</a>]. Because of this association, we suggest limiting the use of glucocorticoids to short courses using low doses. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SKIN INVOLVEMENT</span></p><p class="headingAnchor" id="H7"><span class="h2">Localized scleroderma (morphea)</span><span class="headingEndMark"> — </span>The treatment of localized scleroderma (or morphea) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16150.html" rel="external">"Morphea (localized scleroderma) in adults: Management"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Diffuse skin sclerosis</span><span class="headingEndMark"> — </span>Many patients will present simultaneously with diffuse cutaneous systemic sclerosis (dcSSc) and other disease manifestations requiring immunosuppressive therapies (eg, interstitial lung disease, myocarditis, myositis, arthritis). For these patients, treatment selection is driven by the noncutaneous disease manifestations. In particular, the treatment of interstitial lung disease, myocarditis, and myositis are prioritized because they may lead to potentially life-threatening morbidity.</p><p>In the absence of such disease manifestations, immunosuppression is still used for patients with progressive and diffuse skin involvement. However, most of these treatments demonstrate only a modest benefit, at best, for skin thickening [<a href="#rid8">8-10</a>].</p><p class="headingAnchor" id="H429938930"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>For patients with progressive and diffuse skin involvement, we suggest treatment with either <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), and we initiate therapy as soon as possible, ideally while the skin disease is still active.</p><p>For patients who have other disease manifestations that also require immunosuppression (eg, arthritis, myositis, interstitial lung disease), the choice to use either MTX or MMF is often guided by these other disease manifestations, since there is no evidence that one medication is more efficacious than the other. Some clinicians prefer MTX for patients who also have arthritis or myositis, while others use MMF for patients with significant interstitial lung disease.</p><p>In the absence of other indications for immunosuppression, the choice between MTX and MMF is generally guided by clinician familiarity, local practice, and drug contraindications.</p><p>MMF or MTX is not generally added for dcSSc if the patient is already being treated with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – The dosing and administration of MTX is the same as those used for rheumatoid arthritis, which are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a>.)</p><p></p><p class="bulletIndent1">The efficacy of MTX for the treatment diffuse and progressive skin disease has been evaluated in two randomized, placebo-controlled, double-blind trials [<a href="#rid11">11,12</a>]. Both trials demonstrated an improvement in clinician-assessed skin thickening (the modified Rodnan skin score [mRSS]), although neither result was statistically significant.</p><p></p><p class="bulletIndent1">Another large observational cohort study including 326 patients with early dcSSc (within three years of onset) compared the efficacy of four treatment protocols (MTX, MMF, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and no immunosuppression) and found greater improvement in mRSS among patients receiving immunosuppression, although the differences between groups were not statistically significant [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">Based upon these trials as well as observational data, the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) endorses the use of MTX for progressive skin involvement in the early stages of disease [<a href="#rid3">3</a>]. However, there is no evidence that MTX is effective for visceral organ involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a><strong> mofetil</strong> – The dosing and administration of MMF for dcSSc are the same as those used for interstitial lung disease in SSc, which are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Mycophenolate mofetil'</a>.)</p><p></p><p class="bulletIndent1">A retrospective analysis of Scleroderma Lung Study (SLS) I and SLS-II indicates that MMF is associated with greater improvement in mRSS than placebo for patients with dcSSc [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">The use of MMF for the treatment of skin sclerosis is also supported by small observational studies [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective study including 15 patients with dcSSc found that those who were administered <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> for at least three months demonstrated significant improvement in the mRSS [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another small prospective study with 25 previously untreated patients with dcSSc of recent onset (less than 24 months) also demonstrated improvement of skin involvement after an average of 18 months of therapy with MMF [<a href="#rid15">15</a>]. Skin biopsies from three of the patients demonstrated histopathological improvement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A larger retrospective analysis of 98 patients with dcSSc treated with <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> found improved mRSS compared with baseline within three months of starting treatment [<a href="#rid16">16</a>]. The improved skin score in dcSSc patients treated with mycophenolate persisted during the 12 months of follow-up when compared with historical controls. Unlike <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, MMF is not associated with lung injury. Data supporting the use of MMF for interstitial lung disease are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Mycophenolate mofetil'</a>.)</p><p></p><p class="headingAnchor" id="H4001745547"><span class="h3">Management of resistant disease</span><span class="headingEndMark"> — </span>For patients with skin sclerosis refractory to the aforementioned treatments (defined as lack of improvement in mRSS over three to six months), we suggest other immunosuppressive or immunomodulatory agents such as intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>. Our practice is to reserve such approaches for refractory cases, particularly those who have other features of scleroderma that benefit from immunosuppression. We generally reserve <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for severe rapidly progressive skin thickening when other options cannot be used. Cyclophosphamide may not be as efficacious as rituximab for the treatment of skin disease [<a href="#rid17">17</a>].</p><p>In the context of limited evidence, the choice of therapy depends upon factors such as the presence of other disease manifestations (eg, lung fibrosis, arthritis, or polymyositis), the potential risk of side effects (eg, infection), as well as clinician and patient preference. Interstitial lung disease occurs in over 60 percent of patients with SSc and is therefore a particularly important consideration for many patients [<a href="#rid18">18</a>]. In patients with concomitant skin and lung disease, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> may be preferable, since they have efficacy against both manifestations.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> – The dosing and administration of IVIG are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Intravenous immunoglobulin'</a>.)</p><p></p><p class="bulletIndent1">Small uncontrolled trials have demonstrated improvement in dermal fibrosis using <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> as adjunctive therapy [<a href="#rid19">19</a>]. Additional benefit for other manifestations, such as gastrointestinal complications, has also been reported [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> – The dosing and administration of rituximab are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Rituximab'</a>.)</p><p></p><p class="bulletIndent1">There are also limited data that suggest that <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> has beneficial effects on skin fibrosis [<a href="#rid21">21,22</a>]. However, additional studies are needed to establish the long-term efficacy and safety of rituximab before routine use can be recommended.</p><p></p><p class="bulletIndent1">In a small trial of 56 patients with SSc who were randomly assigned to receive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or placebo, the absolute change in the mRSS was lower in the rituximab group (-6.3 versus 2.14). Among the 48 patients with SSc who also had interstitial lung disease, rituximab was associated with preservation of the forced vital capacity (FVC; change in percent predicted FVC at 24 weeks 0.09 versus -2 percent). The number of adverse events was similar between the two groups [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">A second retrospective study of 29 patients who received <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> 375 mg/m<sup>2</sup> weekly for four weeks indicated a similar improvement in mRSS at the end of one year (median change in mRSS -7) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">The RECITAL clinical trial compared <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> with intravenous <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for connective tissue disease associated interstitial lung disease. Although lung function improved with both, only rituximab was associated with improvement in mRSS at 16 weeks. The difference between the mRSS in the two arms, in an adjusted mixed effects model, was -4.47 units (95% CI -7.99 to -0.95 units, p = 0.013) at 24 weeks in favor of rituximab [<a href="#rid17">17,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a> – The dosing and administration of tocilizumab is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Tocilizumab'</a>.)</p><p></p><p class="bulletIndent1">Data from clinical trials have suggested a potential antifibrotic effect of blocking interleukin 6 (IL-6) signaling using <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid25">25-27</a>].</p><p></p><p class="bulletIndent1">One study of 210 patients with dcSSc demonstrated a statistically significant reduction in the progression of skin fibrosis only for patients with early-stage active skin disease and elevated acute phase reactants [<a href="#rid28">28</a>]. In an open-label extension trial, patients with interstitial lung disease at baseline demonstrated sustained treatment benefit at 96 weeks when compared with patients treated with placebo (change in percent predicted FVC: -3.3 versus -0.5 percent) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">In another study of 51 patients with dcSSc, there was greater improvement in mRSS in patients receiving 48 weeks of weekly subcutaneous <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> compared with placebo, although this difference was not statistically significant (mean change in mRSS -.5.6 versus -3.1) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">One small case series indicates that discontinuation of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> may be associated with disease recrudescence [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> – The dosing and administration of cyclophosphamide are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Intravenous cyclophosphamide'</a>.)</p><p></p><p class="bulletIndent1">We generally reserve the use of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for patients who have severe rapidly progressive skin thickening where other options are not feasible.</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is generally reserved for dcSSc patients with interstitial lung disease, several studies have also reported improvements in skin involvement [<a href="#rid31">31-33</a>].</p><p></p><p class="bulletIndent1">A large multicenter, randomized trial evaluated the efficacy of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> in early active alveolitis in 158 patients with SSc-associated interstitial lung disease. At one-year follow-up, cyclophosphamide therapy improved both lung function and skin scores compared with placebo [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">In a small observational study, 13 patients with early dcSSc were treated with oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and low-dose glucocorticoids for one year and demonstrated a significant improvement in mRSS [<a href="#rid32">32</a>]. However, the effect of glucocorticoid use was not evaluated separately from cyclophosphamide.</p><p></p><p class="headingAnchor" id="H81714483"><span class="h2">Other cutaneous manifestations</span></p><p class="headingAnchor" id="H9"><span class="h3">Pruritus</span><span class="headingEndMark"> — </span>Intense pruritus can occur in the earliest stages of dcSSc, and excessive scratching and excoriation may be a major problem. Pruritus usually decreases as the disease plateaus from 12 to 24 months after onset of skin thickening in diffuse SSc. Up to that point, responses are variable and treatments may need to be used in combination. We suggest the following interventions for as long as the patient is symptomatic:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of environmental triggers, such as heat</p><p class="bulletIndent1"><span class="glyph">●</span>Topical emollients, especially those that are <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">lanolin</a> based</p><p class="bulletIndent1"><span class="glyph">●</span>Counterirritants, such as topical <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> or menthol</p><p class="bulletIndent1"><span class="glyph">●</span>Antihistamines, such as <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> or <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> 25 to 50 mg orally before bedtime</p><p></p><p>For patients who are refractory to these measures, we suggest a short courses of low-dose oral glucocorticoids (eg, less than 10 mg daily dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for less than four weeks). Higher doses of glucocorticoids may increase the risk of developing scleroderma renal crisis. Topical corticosteroids are rarely helpful. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Risk factors'</a>.)</p><p>Alternate therapies include <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>, and <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>, although there are minimal data supporting their use for patients with SSc [<a href="#rid34">34,35</a>].</p><p>A detailed discussion of topical and systemic agents for pruritus may be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Antipruritic therapies'</a> and  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical therapies'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Telangiectasia</span><span class="headingEndMark"> — </span>Telangiectasia can be a cosmetic problem, particularly on the face. These lesions can be camouflaged with makeup. Laser or other light therapy may be useful for particularly large lesions but may recur.</p><p class="headingAnchor" id="H11"><span class="h3">Calcinosis cutis</span><span class="headingEndMark"> — </span>Calcinosis can lead to significant hand disability, can lead to ulceration of the overlying skin, and can become infected.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacotherapy</strong> – In patients with ulceration and/or infection due to calcinosis, we suggest treatment with oral <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, 50 to 100 mg daily for 6 to 12 weeks, in an attempt to resolve the complications and improve pain [<a href="#rid36">36</a>]. If minocycline is ineffective, options include MTX, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. We would use MTX or infliximab preferentially in a patient with concurrent arthritis, and we would use rituximab in a patient with concurrent myositis. However, the evidence to support the use of these agents is limited to case reports [<a href="#rid37">37-39</a>]. We do not recommend treatment with calcium channel blockers, bisphosphonates, or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – We consider surgical removal in patients who fail these therapies and have refractory pain and ulceration. Suitably located lesions can sometimes be removed by using a dental drill; this technique causes less tissue damage than conventional methods [<a href="#rid40">40</a>]. A surgical approach to managing calcinosis cutis in patients with SSc is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7559.html" rel="external">"Hand surgery in patients with systemic sclerosis (scleroderma)", section on 'Treatment of refractory calcinosis cutis'</a>.)</p><p></p><p class="headingAnchor" id="H395558629"><span class="h1">VISCERAL INVOLVEMENT</span></p><p class="headingAnchor" id="H16"><span class="h2">Kidney involvement</span><span class="headingEndMark"> — </span>Scleroderma renal crisis may be accompanied by elevated/rising blood pressure, decreased/declining renal function, and/or proteinuria. Patients with early-stage diffuse cutaneous disease, rapidly progressive cutaneous involvement, or autoantibodies to ribonucleic acid (RNA) polymerase III are at greatest risk for scleroderma renal crisis. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Clinical presentation'</a>.)</p><p>Scleroderma renal crisis is not managed with immunosuppressive therapies. The treatment of patients with scleroderma renal crisis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Gastrointestinal involvement</span><span class="headingEndMark"> — </span>Gastrointestinal involvement is common in systemic sclerosis (SSc) and may involve any or all portions from the mouth to the anus. Assessment of gastrointestinal manifestations is based primarily upon symptomatology. (See  <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">"Gastrointestinal manifestations of systemic sclerosis (scleroderma)"</a>.)</p><p>The treatment of the various gastrointestinal manifestations of SSc is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7556.html" rel="external">"Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Pulmonary involvement</span><span class="headingEndMark"> — </span>The two major types of lung disease in SSc are interstitial lung disease and pulmonary arterial hypertension, which may occur together or separately.</p><p>In general, interstitial lung disease, but not pulmonary arterial hypertension, is managed with immunosuppression. The clinical manifestations, evaluation, and treatment of interstitial lung disease and pulmonary hypertension in patients with SSc are discussed in separate topics. (See  <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening"</a> and  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Cardiac involvement</span><span class="headingEndMark"> — </span>The direct cardiac manifestations of SSc (ie, those not induced by systemic or pulmonary hypertension) include pericarditis, pericardial effusion, myocardial fibrosis, myocarditis, coronary artery disease, and arrhythmias. Efforts by an expert consensus panel to help define primary cardiac involvement in SSc are ongoing [<a href="#rid42">42</a>]. Treatment of the cardiac manifestations is generally based upon the management of similar clinical events in patients without SSc.</p><p class="headingAnchor" id="H28"><span class="h3">Pericarditis</span><span class="headingEndMark"> — </span>Pericarditis typically causes chest pain, but effusive disease causing cardiac tamponade physiology may be painless and may present with dyspnea and edema. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p>Pericarditis in patients with SSc is treated in a similar manner as in patients with pericarditis due to other causes. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p>Cardiac tamponade necessitates drainage of the effusion; treatment of tamponade is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management"</a>.)</p><p>As with other causes of pericarditis, use of glucocorticoids is not advised due to the increased risk of recurrent pericarditis. Also, the use of glucocorticoids may increase the risk of developing scleroderma renal crisis. (See  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Glucocorticoids'</a>.)</p><p>The efficacy of pericardiectomy for recurrent pericardial effusions is uncertain; these issues are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Role of pericardiectomy'</a>.)</p><p class="headingAnchor" id="H1944879292"><span class="h3">Myocarditis</span><span class="headingEndMark"> — </span>Symptoms due to myocardial fibrosis and myocarditis may arise from heart failure due to systolic or more commonly diastolic dysfunction, or they may be due to cardiac rhythm disturbances resulting from interference with normal cardiac electrical conduction (eg, palpitations, syncope). If heart failure is noted in conjunction with an elevation of a marker of cardiac injury, such as the MB fraction of creatine kinase (CK-MB) or troponin-I that is not due to epicardial coronary artery disease, then combination treatment with glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> may be necessary [<a href="#rid43">43</a>]. While there are no established treatment practices for myocarditis associated with SSc, immunosuppressive agents are typically used in a manner comparable to that for the treatment of interstitial lung disease associated with SSc. If cyclophosphamide is not tolerated, we use <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) if the degree of heart failure is less severe. We sometimes use <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> as an alternative. We prefer to use no more than 30 mg of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> daily (or equivalent) due to the risk of scleroderma renal crisis, although this decision must be individualized. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Initiating therapy'</a>.)</p><p class="headingAnchor" id="H3589174029"><span class="h3">Heart failure</span><span class="headingEndMark"> — </span>Heart failure with reduced ejection fraction is treated with standard heart failure treatments, such as angiotensin-converting enzyme (ACE) inhibitors, implantable-cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT). Vasodilating beta blockers may be considered, but often aggravate Raynaud symptoms and may not be tolerated. However, restrictive cardiomyopathy is not likely to respond to these agents.</p><p>Adding a vasodilating calcium channel blocker to standard therapies may lead to additional improvements in cardiac muscle perfusion and function. This was illustrated in a two-week, unblinded study in 18 patients who were examined with cardiac magnetic resonance imaging (MRI) and Doppler echocardiography before and after a two-week trial of <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> (20 mg three times daily) [<a href="#rid44">44</a>]. In a large observational study with over 7000 SSc patients, previous use of calcium channel blockers was associated with a decreased prevalence of left ventricular dysfunction [<a href="#rid45">45</a>]. Whether or not such improvements in perfusion and in systolic and diastolic function are associated with better longer-term outcome is unknown.</p><p>The management of heart failure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Pharmacologic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H1903791548"><span class="h1">MUSCULOSKELETAL INVOLVEMENT</span><span class="headingEndMark"> — </span>Arthralgias and myalgias may be initial features of systemic sclerosis (SSc). Joint symptoms may result from severe skin sclerosis. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Musculoskeletal manifestations'</a>.)</p><p class="headingAnchor" id="H758264611"><span class="h2">Joint involvement</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthralgias – </strong>In patients with arthralgia who do not have arthritis, we typically use nonopioid analgesics such as nonsteroidal antiinflammatory drugs (NSAIDs). Our approach to using NSAIDs for symptomatic relief of arthritis symptoms is presented separately (see  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'NSAIDs'</a>). Alternatively, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (up to 3 g daily in the absence of liver disease or alcohol abuse) may be used if NSAIDs are contraindicated or ineffective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory arthritis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacotherapy</strong> – In patients with inflammatory arthritis associated with SSc, we suggest the following approach:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest treatment with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) 200 to 400 mg daily to control the arthritis. (See  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with persistent arthritis unresponsive to HCQ, we suggest adding <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) [<a href="#rid46">46</a>]. However, MTX should be avoided in patients with severe lung fibrosis due to concerns about pulmonary toxicity. The dose, side effects, monitoring, and other considerations are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Initial therapy with methotrexate'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We generally avoid glucocorticoids because of the risk of precipitating scleroderma renal crisis. However, for patients with debilitating inflammatory arthritis , we use low-dose glucocorticoids (ie, less than 10 mg daily dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent) for a short period (ie, less than two to four weeks) to achieve rapid disease control.</p><p></p><p class="bulletIndent2">For patients with persistent arthritis unresponsive to HCQ and/or MTX, the alternative disease-modifying antirheumatic drug (DMARD) should take into account the severity of the arthritis as well as patient preference. Patients with rheumatoid factor and/or anti-citrullinated peptide positivity may have an overlap syndrome and require more aggressive therapy (see  <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"</a>). Biologic agents used to treat rheumatoid arthritis, including tumor necrosis factor (TNF) inhibitors, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, and Janus kinase (JAK) inhibitors can be used [<a href="#rid47">47-53</a>].</p><p></p><p class="bulletIndent2">The management of SSc-associated inflammatory arthritis is similar to the management of rheumatoid arthritis, which is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical therapy</strong> – Physical therapy is important in limiting contractures, which can occur quite rapidly. Therapy should include both active and passive exercises. Adequate analgesia may be required to permit a regular daily regimen. Encouragement from the therapist and clinician is also critical if a regular program is to be performed. The patient should appreciate that skin involvement ultimately plateaus and that the purpose of physical therapy is to limit the loss of function before such plateauing of skin involvement occurs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery</strong> – Surgery has an uncertain role in this setting [<a href="#rid54">54</a>]. Realignment of contracted fingers by straightening, shortening, and fusing of interphalangeal joints may improve the appearance and may decrease the development of digital ulcers. However, such procedures may not greatly improve function. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7559.html" rel="external">"Hand surgery in patients with systemic sclerosis (scleroderma)"</a>.)</p><p></p><p class="headingAnchor" id="H2958828295"><span class="h2">Inflammatory myopathy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentations</strong> – A mild myopathy with little biochemical or histologic change is a common feature of SSc. A smaller group of patients have an inflammatory myopathy that is clinically and histologically similar to polymyositis. Certain SSc-associated autoantibodies are associated more frequently with myositis such as anti-PM-Scl, anti-Ku, and anti-U3-RNP (fibrillarin) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/7550.html" rel="external">"Neuromuscular manifestations of systemic sclerosis (scleroderma)", section on 'Myopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of patients with SSc and an inflammatory myopathy is similar to that for patients with idiopathic polymyositis. Low-dose glucocorticoids alone or in combination with MTX, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, or other immunosuppressive agents are generally employed. (See  <a class="medical medical_review" href="/z/d/html/7550.html" rel="external">"Neuromuscular manifestations of systemic sclerosis (scleroderma)", section on 'Myopathy'</a>.)</p><p></p><p class="bulletIndent1">High-dose glucocorticoids, above <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 mg daily (or equivalent), should generally be avoided in this setting because of an increased risk of precipitating scleroderma renal crisis [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H353539269"><span class="h1">VASCULAR INVOLVEMENT</span></p><p class="headingAnchor" id="H2970918981"><span class="h2">Raynaud phenomenon</span><span class="headingEndMark"> — </span>Vascular involvement is a prominent feature of systemic sclerosis (SSc). Vasoconstriction and obliterative vasculopathy likely contribute to Raynaud phenomenon, scleroderma renal crisis, pulmonary hypertension, and other visceral disease.</p><p>Treatment of Raynaud phenomenon is generally the same in patients with and without SSc. (See  <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a>.)</p><p class="headingAnchor" id="H3731398906"><span class="h2">Erectile dysfunction</span><span class="headingEndMark"> — </span>Erectile dysfunction (ED) is common in men with SSc, resulting from impaired penile blood flow due both to myointimal proliferation of small arteries and to corporal fibrosis [<a href="#rid56">56</a>].</p><p>We suggest fixed daily or alternate day regimens of long-acting phosphodiesterase type-5 (PDE-5) inhibitors (eg, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>) [<a href="#rid56">56</a>], after addressing modifiable or reversible risk factors for ED, including lifestyle, psychological, or drug-related factors [<a href="#rid57">57</a>]. Treatment with on-demand PDE-5 inhibitors (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>) is usually not effective. Consultation with a urologist may be of benefit if other approaches are required.</p><p>These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction"</a>.)</p><p class="headingAnchor" id="H1515104155"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>All patients require screening at routine intervals for the development of major organ complications, particularly cardiac disease, interstitial lung disease, pulmonary hypertension, and kidney involvement. The frequency of these evaluations may depend on the patient’s prior history, time since initial diagnosis, and autoantibody status.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac disease</strong> – To monitor for cardiac disease, we suggest an annual echocardiogram and electrocardiogram for all patients. Additional laboratory tests may be necessary for patients suspected of having specific disease manifestations (eg, myocarditis, heart failure)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial lung disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary function testing</strong> – For patients without a known history of lung involvement, we obtain annual pulmonary function tests (ie, spirometry, diffusing capacity, exertional pulse oxygenation saturation) for five years after the initial diagnosis. We decrease the frequency of pulmonary function tests to once every two years under the following circumstances:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Systemic sclerosis (SSc) for longer than five years, normal exercise capacity, and normal diffusing capacity for carbon monoxide (DLCO) on pulmonary function tests</p><p class="bulletIndent3"><span class="glyph">-</span>Stable pulmonary function tests for at least three years</p><p></p><p>Patients with preexisting lung involvement may require more frequent pulmonary function testing, depending on their clinical stability. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Monitoring response to therapy'</a>.).</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Computed tomography</strong> – High-resolution CT (HRCT) should be performed to evaluate changes in pulmonary symptoms or pulmonary function tests.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension</strong> – In addition to an annual echocardiogram, we obtain a plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) annually for the following types of patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SSc for longer than three years</p><p class="bulletIndent2"><span class="glyph">•</span>Low diffusing capacity on pulmonary function testing</p><p></p><p>Patients who may have worsening pulmonary hypertension (eg, declining diffusing capacity on pulmonary function testing, or new or worsening pulmonary symptoms) may require more frequent NT-proBNP testing</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney disease</strong> – We suggest checking blood pressure twice weekly for all patients. We suggest daily home blood pressure measurements for the following types of patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early-stage diffuse cutaneous disease</p><p class="bulletIndent2"><span class="glyph">•</span>Rapidly progressive cutaneous involvement with tendon friction rubs</p><p class="bulletIndent2"><span class="glyph">•</span>Autoantibodies to RNA polymerase III</p><p></p><p>An increase in systolic blood pressure of 15 mmHg or diastolic blood pressure of 10 mmHg should trigger an immediate evaluation for scleroderma renal crisis. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Establishing the diagnosis'</a>.)</p><p>Screening recommendations are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Evaluation for lung disease at time of SSc presentation'</a> and  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Screening'</a> and  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Surveillance'</a> and  <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Subsequent monitoring'</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H33"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>There is a substantial increase in the risk of death in patients with systemic sclerosis (SSc). Most deaths among patients with SSc are related to pulmonary fibrosis, pulmonary arterial hypertension, or cardiac causes [<a href="#rid58">58-60</a>]. Other significant causes of death include kidney disease, malignancy, and gastrointestinal and infectious causes [<a href="#rid60">60</a>]. The overall survival of patients with SSc has improved over time, but the proportion of deaths related to SSc has increased.</p><p>In a meta-analysis of 2691 SSc patients followed over 40 years, the standardized mortality ratio (SMR) was almost four times higher among SSc patients versus age- and sex-matched controls in the general population (SMR 3.5, 95% CI 3.03-4.11) [<a href="#rid61">61</a>]. Among 732 deaths, 389 (53 percent) were considered to be related to SSc, whereas 223 (30 percent) deaths were defined as not related to SSc, and 120 deaths (16 percent) were due to unknown causes. Of the 612 deaths from known causes, heart involvement was the most frequent cause of death (29 percent), followed by lung involvement (23 percent), cancer (16 percent), and kidney involvement (11 percent). </p><p>Well-characterized cohorts of SSc have reported improvements in survival compared with older cohorts [<a href="#rid62">62</a>] especially in the diffuse subset [<a href="#rid63">63</a>]. Additionally, outcomes for complications such as pulmonary hypertension have improved, likely due to better management strategies [<a href="#rid64">64</a>]. However, a meta-analysis of 2719 deaths in patients with SSc indicates that there has been an increase in SSc-specific mortality over time [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H34"><span class="h2">Risk factors for increased mortality</span><span class="headingEndMark"> — </span>Various risk factors have been associated with increased mortality, including the presence of extensive skin involvement, cardiac and/or pulmonary involvement, renal disease, and the presence of anti-topoisomerase I antibodies and/or anti-Th/To antibodies [<a href="#rid58">58,60,66-69</a>]. Male sex has been associated with increased mortality in some but not all studies [<a href="#rid70">70,71</a>]. Younger age at disease onset is also associated with a higher risk of mortality [<a href="#rid72">72</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extensive skin involvement</strong> – Several studies have demonstrated that patients with diffuse cutaneous SSc (dcSSc) have higher mortality than patients with limited cutaneous SSc (lcSSc) [<a href="#rid66">66,73-75</a>]. Two cohort studies of 1012 and 309 patients found lower 10-year survival among those with diffuse skin disease compared with those with lcSSc (53 to 62 percent versus 75 to 79 percent, respectively) [<a href="#rid73">73,74</a>]. A large meta-analysis including 3311 European, Japanese, and North American patients also noted an increased risk of premature death in those with diffuse skin involvement (adjusted hazard ratio [HR] 1.2, 95% CI 1.0-1.4) [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">Among those with dcSSc, severe skin sclerosis, as assessed by skin score, is associated with increased mortality. This was illustrated in a study of 225 patients with diffuse skin disease [<a href="#rid67">67</a>]. Those with severe involvement (modified Rodnan skin score [mRSS] ≥35) had significantly greater cumulative mortality when compared with those with less skin sclerosis (37 and 21 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibody status</strong> – A cohort study of 10,711 patients demonstrated that scleroderma-specific autoantibodies were better than skin involvement at predicting overall survival, disease progression, scleroderma renal crisis, and pulmonary fibrosis after four years of follow-up [<a href="#rid76">76</a>]. Anti-topoisomerase I, anti-Th/To, and anti-RNA polymerase III antibodies are all associated with increased mortality [<a href="#rid66">66,69,76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary involvement</strong> – The prognosis of patients with specific pulmonary manifestations, including pulmonary arterial hypertension and interstitial lung disease, is presented separately. (See  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening"</a> and  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Prognosis'</a>.)</p><p></p><p class="headingAnchor" id="H2678760694"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118282.html" rel="external">"Society guideline links: Systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H27624986"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – In general, patients with systemic sclerosis (SSc; scleroderma) are treated with organ-based symptomatic therapy. However, patients with diffuse skin involvement and/or severe inflammatory organ involvement are usually treated with systemic immunosuppressive therapy. We avoid glucocorticoids whenever possible due to their association with scleroderma renal crisis; if necessary, we treat with short courses of low-dose glucocorticoids. (See <a class="local">'General principles of management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse skin sclerosis</strong> – For patients with progressive and diffuse skin involvement, we suggest treatment with either <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) rather than <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with other disease manifestations that also require immunosuppression (eg, arthritis, myositis, interstitial lung disease), the choice of immunosuppression is often guided by the presence of other disease manifestations, since there is no evidence that one medication is more efficacious than the other. We use MTX for patients who also have arthritis or myositis, we use and MMF for patients with interstitial lung disease.</p><p></p><p class="bulletIndent1">For patients with resistant disease, we suggest intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>), <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally reserve <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for progressive skin involvement in patients who are refractory to treatment with either MTX or MMF or who have severe rapidly progressive skin thickening. (See <a class="local">'Skin involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cutaneous manifestations</strong> – For patients with pruritus, we use topical emollients (eg, <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">lanolin</a>), counterirritants (eg, topical <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a>, menthol), and antihistamines (eg, <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>). (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical therapies'</a>.)</p><p></p><p class="bulletIndent1">For refractory pruritus, we suggest a short course of low-dose oral glucocorticoids (eg, less than 10 mg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> daily for less than four weeks) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1">Patients may conceal telangiectasis with cosmetics. We treat larger telangiectasias with laser therapy.</p><p></p><p class="bulletIndent1">For patients with calcinosis cutis, we suggest treatment with <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). When calcinosis cutis is refractory to minocycline, options include MTX, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. We consider surgical removal of lesions for patients with significant pain and disability. (See <a class="local">'Other cutaneous manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral involvement</strong> – Many forms of visceral involvement, including scleroderma renal crisis, gastrointestinal dysmotility, heart failure, and pulmonary hypertension, are not managed with immunosuppression.</p><p></p><p class="bulletIndent1">Interstitial lung disease, myocarditis, and pericarditis require immunosuppressive therapies, but we attempt to avoid glucocorticoids, which may precipitate scleroderma renal crisis.</p><p></p><p class="bulletIndent1">Management of specific organ involvement is discussed elsewhere:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">"Gastrointestinal manifestations of systemic sclerosis (scleroderma)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Initiating therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis", section on 'Pulmonary arterial hypertension-directed therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/120198.html" rel="external">"Cardiac manifestations of systemic sclerosis (scleroderma)", section on 'Cardiac manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal involvement</strong> – We treat arthralgias with nonsteroidal antiinflammatory drugs (NSAIDs). We suggest <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) for treatment of inflammatory arthritis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We add MTX for patients with refractory symptoms. For patients with inflammatory arthritis, physical and occupational therapy helps prevent contractures, but the role of surgery is uncertain. (See <a class="local">'Musculoskeletal involvement'</a> above.)</p><p></p><p class="bulletIndent1">We treat inflammatory myopathy using the same strategies used for idiopathic polymyositis. However, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> above 20 mg daily (or equivalent) should be avoided, to prevent precipitating scleroderma renal crisis. (See  <a class="medical medical_review" href="/z/d/html/7550.html" rel="external">"Neuromuscular manifestations of systemic sclerosis (scleroderma)", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular involvement</strong> – Raynaud phenomenon is the hallmark of SSc and is treated similarly to patients without SSc. (See  <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management"</a>.)</p><p></p><p class="bulletIndent1">For erectile dysfunction (ED) that persists after addressing modifiable or reversible risk factors, we suggest fixed daily or alternate-day regimens of long-acting phosphodiesterase type-5 (PDE-5) inhibitors (eg, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> 2.5 to 5 mg once daily) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Vascular involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – All patients require screening at routine intervals for the development of major organ complications, particularly cardiac disease, interstitial lung disease, pulmonary hypertension, and kidney involvement. The frequency of monitoring depends on the patient’s prior history, time since initial diagnosis, and autoantibody status. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In general, we obtain an annual echocardiogram and electrocardiogram for all patients. We also monitor blood pressure twice weekly. (See  <a class="medical medical_review" href="/z/d/html/120198.html" rel="external">"Cardiac manifestations of systemic sclerosis (scleroderma)", section on 'Screening for cardiac involvement'</a> and  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Echocardiography'</a> and  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Surveillance'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain annual pulmonary function tests for at least five years following diagnosis to monitor for interstitial lung disease; after that, less frequent monitoring is reasonable for patients with stable findings. Patients with known interstitial lung disease may require more frequent testing. Changes in symptoms or pulmonary function tests should be followed by high-resolution CT. (See  <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Diagnosis of lung disease in systemic sclerosis'</a>.)</p><p></p><p class="bulletIndent2">In patients with SSc for longer than three years or who have a low diffusing capacity for carbon monoxide (DLCO), we test plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) annually to monitor for pulmonary hypertension. (See  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Abnormal pulmonary function (low diffusion)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We check blood pressure daily in patients with early-stage diffuse cutaneous disease, rapidly progressive cutaneous involvement with tendon friction rubs, or autoantibodies to RNA polymerase III to monitor for scleroderma renal crisis. An increase in systolic blood pressure of 15 mmHg or diastolic blood pressure of 10 mmHg should trigger an immediate evaluation for scleroderma renal crisis. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Establishing the diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – There is a substantial increase in the risk of death in patients with SSc. Most deaths among patients with SSc are related to pulmonary fibrosis, pulmonary arterial hypertension, or cardiac causes. Other significant causes of death include kidney disease, malignancy, gastrointestinal, and infectious causes. (See <a class="local">'Mortality'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol 2020; 72:465.</a></li><li><a class="nounderline abstract_t">Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 2016; 55:1906.</a></li><li><a class="nounderline abstract_t">Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76:1327.</a></li><li><a class="nounderline abstract_t">van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311:2490.</a></li><li><a class="nounderline abstract_t">Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378:35.</a></li><li class="breakAll">ClinicalTrials.gov. National Library of Medicine. https://clinicaltrials.gov/.</li><li><a class="nounderline abstract_t">Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41:1613.</a></li><li><a class="nounderline abstract_t">Herrick AL, Lunt M, Whidby N, et al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010; 37:116.</a></li><li><a class="nounderline abstract_t">Frech TM, Shanmugam VK, Shah AA, et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013; 31:166.</a></li><li><a class="nounderline abstract_t">Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 2017; 76:1207.</a></li><li><a class="nounderline abstract_t">van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35:364.</a></li><li><a class="nounderline abstract_t">Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44:1351.</a></li><li><a class="nounderline abstract_t">Namas R, Tashkin DP, Furst DE, et al. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken) 2018; 70:439.</a></li><li><a class="nounderline abstract_t">Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009; 48:1595.</a></li><li><a class="nounderline abstract_t">Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39:1241.</a></li><li><a class="nounderline abstract_t">Le EN, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70:1104.</a></li><li><a class="nounderline abstract_t">Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 2023; 11:45.</a></li><li><a class="nounderline abstract_t">Suliman YA, Dobrota R, Huscher D, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol 2015; 67:3256.</a></li><li><a class="nounderline abstract_t">Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 2015; 42:236.</a></li><li><a class="nounderline abstract_t">Raja J, Nihtyanova SI, Murray CD, et al. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 2015.</a></li><li><a class="nounderline abstract_t">Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74:1188.</a></li><li><a class="nounderline abstract_t">Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3:e489.</a></li><li><a class="nounderline abstract_t">Kuzumi A, Ebata S, Fukasawa T, et al. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels. JAMA Dermatol 2023; 159:374.</a></li><li class="breakAll">Maher T, Tudor M, Saunders P, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): A sub-group analysis of a mult-centre randomised controlled trial. Abstract, American College of Rheumatology Convergence meeting, Philadelphia, PA, November 2022.</li><li><a class="nounderline abstract_t">Denton CP, Ong VH, Xu S, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 2018; 77:1362.</a></li><li><a class="nounderline abstract_t">Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387:2630.</a></li><li><a class="nounderline abstract_t">Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018; 77:212.</a></li><li><a class="nounderline abstract_t">Ghuman A, Khanna D, Lin CJF, et al. Prognostic and predictive markers of systemic sclerosis-interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford) 2023.</a></li><li><a class="nounderline abstract_t">Khanna D, Lin CJF, Furst DE, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med 2022; 205:674.</a></li><li><a class="nounderline abstract_t">Isomura Y, Shirai Y, Kuwana M. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology (Oxford) 2022; 61:4491.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655.</a></li><li><a class="nounderline abstract_t">Apras S, Ertenli I, Ozbalkan Z, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48:2256.</a></li><li><a class="nounderline abstract_t">Tehlirian CV, Hummers LK, White B, et al. High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 2008; 67:775.</a></li><li><a class="nounderline abstract_t">Frech TM, Baron M. Understanding itch in systemic sclerosis in order to improve patient quality of life. Clin Exp Rheumatol 2013; 31:81.</a></li><li><a class="nounderline abstract_t">Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol 2011; 2011:804296.</a></li><li><a class="nounderline abstract_t">Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003; 62:267.</a></li><li><a class="nounderline abstract_t">Tosounidou S, MacDonald H, Situnayake D. Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome. Rheumatology (Oxford) 2014; 53:960.</a></li><li><a class="nounderline abstract_t">de Paula DR, Klem FB, Lorencetti PG, et al. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013; 32:281.</a></li><li><a class="nounderline abstract_t">Daoussis D, Antonopoulos I, Liossis SN, et al. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012; 41:822.</a></li><li><a class="nounderline abstract_t">Lapner MA, Goetz TJ. High-speed burr debulking of digital calcinosis cutis in scleroderma patients. J Hand Surg Am 2014; 39:503.</a></li><li><a class="nounderline abstract_t">Reiter N, El-Shabrawi L, Leinweber B, et al. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 2011; 65:15.</a></li><li><a class="nounderline abstract_t">Bruni C, Buch MH, Furst DE, et al. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord 2022; 7:24.</a></li><li><a class="nounderline abstract_t">Pieroni M, De Santis M, Zizzo G, et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014; 43:526.</a></li><li><a class="nounderline abstract_t">Vignaux O, Allanore Y, Meune C, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005; 64:1268.</a></li><li><a class="nounderline abstract_t">Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69:218.</a></li><li><a class="nounderline abstract_t">Avouac J, Clements PJ, Khanna D, et al. Articular involvement in systemic sclerosis. Rheumatology (Oxford) 2012; 51:1347.</a></li><li><a class="nounderline abstract_t">Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013; 72:1217.</a></li><li><a class="nounderline abstract_t">Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012; 30:S55.</a></li><li><a class="nounderline abstract_t">Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34:1636.</a></li><li><a class="nounderline abstract_t">Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329:1266.</a></li><li><a class="nounderline abstract_t">Allanore Y, Devos-François G, Caramella C, et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65:834.</a></li><li><a class="nounderline abstract_t">Kyriakou A, Parperis K, Nikiphorou E, Psarelis S. Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review. Rheumatol Int 2021; 41:671.</a></li><li><a class="nounderline abstract_t">Khanna D, Padilla C, Tsoi LC, et al. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight 2022; 7.</a></li><li><a class="nounderline abstract_t">Jones NF, Imbriglia JE, Steen VD, Medsger TA. Surgery for scleroderma of the hand. J Hand Surg Am 1987; 12:391.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6:112.</a></li><li><a class="nounderline abstract_t">Walker UA, Tyndall A, Ruszat R. Erectile dysfunction in systemic sclerosis. Ann Rheum Dis 2009; 68:1083.</a></li><li><a class="nounderline abstract_t">Foocharoen C, Tyndall A, Hachulla E, et al. Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther 2012; 14:R37.</a></li><li><a class="nounderline abstract_t">Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269.</a></li><li><a class="nounderline abstract_t">Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940.</a></li><li><a class="nounderline abstract_t">Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809.</a></li><li><a class="nounderline abstract_t">Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51:1017.</a></li><li><a class="nounderline abstract_t">Cacciapaglia F, Airò P, Fornaro M, et al. Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients. Rheumatology (Oxford) 2023; 62:1552.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103:109.</a></li><li><a class="nounderline abstract_t">Mullin CJ, Khair RM, Damico RL, et al. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol 2019; 71:1691.</a></li><li><a class="nounderline abstract_t">Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76:1897.</a></li><li><a class="nounderline abstract_t">Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2.</a></li><li><a class="nounderline abstract_t">Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56:2422.</a></li><li><a class="nounderline abstract_t">Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 2014; 26:131.</a></li><li><a class="nounderline abstract_t">Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48:203.</a></li><li><a class="nounderline abstract_t">Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012; 39:1971.</a></li><li><a class="nounderline abstract_t">Ngian GS, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14:R213.</a></li><li><a class="nounderline abstract_t">Alba MA, Velasco C, Simeón CP, et al. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) 2014; 93:73.</a></li><li><a class="nounderline abstract_t">Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.</a></li><li><a class="nounderline abstract_t">Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66:1625.</a></li><li><a class="nounderline abstract_t">Muriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. Lancet Rheumatol 2022; 4:e785.</a></li></ol></div><div id="topicVersionRevision">Topic 7542 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682743" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284161" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : BSR and BHPR guideline for the treatment of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941129" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Update of EULAR recommendations for the treatment of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058083" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29298160" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29298160" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751093" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955050" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23910619" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of early diffuse systemic sclerosis skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188239" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11407694" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28544580" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846575" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467932" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378404" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36375479" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316389" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25433527" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24442885" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38279402" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36790794" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36790794" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29853453" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27156934" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066464" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37228011" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prognostic and predictive markers of systemic sclerosis-interstitial lung disease in a clinical trial and long-term observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34851799" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35258561" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790698" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cyclophosphamide versus placebo in scleroderma lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12905480" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974598" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-dose cyclophosphamide without stem cell rescue in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23910614" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Understanding itch in systemic sclerosis in order to improve patient quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21918649" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Low-dose naltrexone for pruritus in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594118" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24255162" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23179007" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rituximab-induced regression of CREST-related calcinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221908" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24559627" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-speed burr debulking of digital calcinosis cutis in scleroderma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679811" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Calcinosis cutis: part II. Treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35386946" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932313" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708883" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19279015" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467084" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Articular involvement in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253926" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691210" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611970" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564258" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16699057" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33433730" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35943798" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584887" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Surgery for scleroderma of the hand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20125179" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Autoantibodies as predictive tools in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19525406" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Erectile dysfunction in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22348608" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18706680" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Determinants of morbidity and mortality of systemic sclerosis in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329309" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Changes in causes of death in systemic sclerosis, 1972-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20551155" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900368" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36074979" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966313" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31066998" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835464" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mapping and predicting mortality from systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639201" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mortality in systemic sclerosis: an international meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599771" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24441644" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528120" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22896025" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23039366" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646463" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889413" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889414" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24591477" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prediction of pulmonary complications and long-term survival in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
